Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9-Benzyladenine

References

Page 1

	Year	Citations
Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta Claire Lugnier, Philippe Schoeffter, Alain Le Bec, Biochemical Pharmacology Selective InhibitionBiochemistryMedicineVascular PharmacologyPhysiology	1986	296
Stereospecific binding of the antidepressant rolipram to brain protein structures Herbert H. Schneider, Ralph Schmiechen, Marina Brezinski, European Journal of Pharmacology PsychiatryNeuroanatomyMedicineNeuropeptide ReceptorNeuropharmacology	1986	236
Neutrophil-mediated Pulmonary Vascular Injury: Synergistic Effect of Trace Amounts of Lipopolysaccharide and Neutrophil Stimuli on Vascular Permeability and Neutrophil Sequestration in the Lung G. Scott Worthen, Christopher Haslett, A. J. Rees, American Review of Respiratory Disease Acute Lung InjuryLung InflammationImmunologyOxidative StressInflammation	1987	227
The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells J. Semmler, H. Wachtell, Stefan Endres International Journal of Immunopharmacology InflammationThrombopoiesisAnti-inflammatoryMedicineHuman Mononuclear Cells	1993	221
The Association of Circulating Endotoxin with the Development of the Adult Respiratory Distress Syndrome Polly E. Parsons, G. Scott Worthen, Ernest E. Moore, American Review of Respiratory Disease	1989	180
Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages Taku Kambayashi, Chaim O. Jacob, Dandan Zhou, The Journal of Immunology	1995	159
Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [<sup>3</sup>H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret Allen J. Duplantier, Michael S. Biggers, Robert Chambers, Journal of Medicinal Chemistry	1996	143
SB 207499 (Ariflo), a Potent and Selective Second-Generation Phosphodiesterase 4 Inhibitor: In Vitro Anti-inflammatory Actions Mary S. Barnette, S. Brøgger Christensen, David M. Essayan, Journal of Pharmacology and Experimental Therapeutics	1998	140
Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor Uma Prabhakar, David B. Lipshutz, Joan O'Leary Bartus, International Journal of Immunopharmacology Molecular PharmacologySignal TransductionBiochemistryMedicinePde Iv	1994	137
Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. Theodore J. Torphy, Han-liang Zhou, L B Cieslinski Journal of Pharmacology and Experimental Therapeutics	1992	124

Page 1